Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.
The addition of atezolizumab to standard of care (SOC) carboplatin and etoposide appears to improve overall survival (OS) and progression-free survival (PFS) in patients with extensive stage small cell lung cancer (ES-SCLC), setting in place a potential new SOC, according to the IMpower133* trial findings.
New drug applications approved by US FDA as of 01 - 15 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Alectinib shows significantly improved efficacy in terms of progression-free survival (PFS) over crizotinib in the first-line setting, yet again, this time involving Asian patients with ALK+ NSCLC in the ALESIA* study, consistent with previous findings in a global population.
Adaptive radiotherapy (RT) guided by 18F-FDG PET/CT functional imaging improves objective response rate (ORR) and survival in non-small-cell lung cancer (NSCLC) without increasing toxicity compared with conventional RT, a small study conducted in China has shown.
Adding cetuximab to afatinib does not improve overall survival (OS), progression-free survival (PFS) or objective response rate (ORR) in the first-line treatment of patients with advanced or recurrent non-small-cell lung cancer (NSCLC) harbouring classical sensitizing EGFR mutations.
Atezolizumab, when added to standard-of-care chemotherapy, significantly improves survival of patients with extensive-stage small-cell lung cancer (SCLC) in the first-line setting, according to results of the IMpower133 trial reported at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).
Population-based lung cancer screening with multislice CT substantially reduces mortality from the disease among high-risk former and current smokers, with larger risk reductions in women vs men, the NELSON study has shown.
Incorporating reflex testing with a novel next-generation sequencing (NGS) assay with an expanded array of biomarkers was reliable, cost-effective, and efficient in profiling the genomes of patients with advanced non-small-cell lung cancer (NSCLC), thus enabling efficient initiation of targeted therapies for the patients, a new study shows.
Assoc Prof Philip Eng, senior consultant respiratory physician at Mt Elizabeth Hospital in Singapore, shares his insights with Pearl Toh on diagnosing and managing pneumonia in the primary care setting.
Extended preloading of varenicline for 6 weeks before the target quit day (TQD) safely improves the efficacy of the prescription medication in facilitating smoking cessation at 12 weeks and at 6 months, according to a study presented at the American Thoracic Society (ATS) 2019 International Conference, held at Dallas, Texas in the US.